Thera-SAbDab

ENSITUXIMAB

>   Structural Summary
TherapeuticEnsituximab
TargetMUC5AC
Heavy ChainQVQLKESGPDLVAPSQSLSITCTVSGFSLSKFGVNWVRQPPGKGLEWLGVIWGDGSTSYNSGLISRLSISKENSKSQVFLKLNSLQADDTATYYCVKPGGDYWGHGTSVTVSS
Light ChainQVVLTQSPVIMSASPGEKVTMTCSASSSISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISNMEAGDAATYYCHQRDSYPWTFGGGTNLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedNeogenix Oncology, Duke University Medical Center, H. Lee Moffitt Cancer Center and Research Institute, Johns Hopkins Medical Institutions, Montefiore Medical Center, National Cancer Institute (USA), Precision Biologics, University of North Carolina, University of Texas Southwestern Medical Center, Yale University School of Medicine
Conditions Approvedna
Conditions ActiveColorectal cancer, Pancreatic cancer
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]